Your browser doesn't support javascript.
loading
Indolent T Cell Lymphoproliferation of the Gastrointestinal Tract: An Evolving Disease Entity.
Wang, Luke; Koh, Elaine; Kumar, Beena; Low, Michael S Y.
Afiliação
  • Wang L; Monash Health, Monash Medical Centre, Clayton, VIC 3168, Australia.
  • Koh E; Monash Health, Monash Medical Centre, Clayton, VIC 3168, Australia.
  • Kumar B; Department of Anatomical Pathology, Monash Health, Clayton, VIC 3168, Australia.
  • Low MSY; Monash Haematology, Monash Health, Clayton, VIC 3168, Australia.
Hematol Rep ; 16(2): 179-184, 2024 Mar 22.
Article em En | MEDLINE | ID: mdl-38525693
ABSTRACT

Background:

Indolent T cell lymphoproliferation of the gastrointestinal tract is a novel entity recently added to the 2016 WHO classification of lymphoid neoplasms. Classically, these patients demonstrate an immunophenotype consistent with T cell proliferation and can be either CD4-positive or CD8-positive but with a low Ki67 index, highlighting the indolent nature of this disease compared to its more aggressive T cell lymphoma counterparts such as enteropathy-associated T cell lymphoma and monomorphic epitheliotropic intestinal T cell lymphoma.

Methods:

Here, we describe one rare case of such a neoplasm under our care, initially presenting with non-specific signs and symptoms and requiring extensive investigations to diagnose. Available cases in the literature reflect a wide variety of ages and ethnicities affected, and any part of the gastrointestinal sites can be affected, which makes diagnosis difficult and prolonged; however, progression beyond lymph nodes is rare, and prognosis is otherwise favourable, particularly if CD8-positive. The optimal management of these patients remains yet to be defined, given the paucity of available cases currently. The current evidence suggests the utility of steroids, cyclosporine, radiotherapy, and a potential role for JAK inhibitors.

Conclusions:

Our case showed an excellent response to the initial course of steroids, with a subsequent successful transition to cyclosporine, keeping symptoms at bay with ongoing stable disease.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article